Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation

BACKGROUND: Immune modifications, including changes in interleukin (IL)-6 levels, have often been observed in major depressive disorder (MDD) during treatment with selective serotonin reuptake inhibitors (SSRIs) or the serotonin norepinephrine reuptake inhibitor (SNRI) venlafaxine. Nevertheless, no...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fornaro, Michele, Martino, Matteo, Battaglia, Florinda, Colicchio, Salvatore, Perugi, Giulio
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2011
Materias:
Short Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3056173/
https://ncbi.nlm.nih.gov/pubmed/21430794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S16382
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares